Tis 26 sep / År 41 / Nr 3 2023

Answering the need for specialised diagnostics

The ever-increasing pressure on healthcare budgets has resulted in various cost-cutting exercises affecting most disciplines and areas of care. This has placed extended pressure also on diagnostic testing, demanding quicker and more accurate diagnostic tools – and always at a lower cost. In the face of these challenges, the Malmö-based full-service diagnostics company Euro Diagnostica has developed complete solutions in autoimmunity testing..

“As autoimmune diseases are on the rise across the globe, the need for specialised diagnostics targeting these diseases has never been greater than now”, says Euro Diagnostica CEO Else Beth Trautner initially.

20 years of development
Euro Diagnostica has dedicated over 20 years to develop safe, efficient and accurate testing solutions for autoimmune diseases. Although the underlying causes of autoimmunity still remain unknown, there have been some major breakthroughs in providing faster and better diagnostic tools for autoimmune diseases such as Celiac disease, Crohn’s disease and rheumatoid arthritis.
“Providing the correct diagnosis is the first step on the road to treatment. We hereby have a very important part to play in the continuum of care, as we provide the means necessary to establish accurate and reliable diagnosis of autoimmune diseases”, Else Beth Trautner confirms.
The aim is primarily to reduce patient suffering by enabling faster treatment based on correct diagnosis. Time is crucial, further development of the disease can be halted if correct diagnosis can be established and treatment commenced quickly. But there is also the aspect of cost, where the biopharmaceuticals used to treat many autoimmune diseases are among the most expensive treatments available today. There is, in other words, a lot more to be gained from using reliable diagnostic tools and thus being able to establish correct diagnosis fast.

Closer to personalised answers
Euro Diagnostica maintains a high level of innovation and continues to invest in product development activities while at the same time meeting increased market demands regarding cost-effectiveness and proof of efficacy. In addition, the recent merger-agreement with Biomonitor grants access to a much wider market through the fields of theranostics and personalized medicine.
“Our merger-agreement with Biomonitor brings us closer to our mission of providing personalised answers to patients. It is also a perfect example of how we are striving to utilize opportunities throughout the entire Oresund region, on both sides of the bridge. If we want to compete globally, we must create stronger collaborations locally – meaning throughout Medicon Valley and the entire Oresund region”, Else Beth Trautner explains.

Even better solutions
As well as a wide range of diagnostic tools, Euro Diagnostica can now offer patient-monitoring solutions and assay development for new biopharmaceuticals.
“Biomonitor’s expertise complements our own strengths and enhances our position as a full-service diagnostics partner. There is no doubt in that the need for safe and reliable testing is now greater than ever. We can now provide even better solutions for faster drug development and optimised diagnosis through our merged companies”, concludes Else Beth Trautner.